MMP-2 Inhibitor

Pipoxolan hydrochloride is an anti-spasmotic agent. Pipoxolan hydrochloride induces Apoptosis, increases intracellular ROS. Pipoxolan hydrochloride down-regulates phosphorylation JNK and p38, and then, MMP-2 and -9. Pipoxolan hydrochloride relieves smooth muscle spasms in the digestive, urinary, and gynecological systems. Pipoxolan hydrochloride also exhibits anticancer activity against leukemia, oral squamous cell carcinoma, and lung adenocarcinoma.

SC-77964 is a potent, selective and orally active matrix metalloprotease (MMP) inhibitor. SC-77964 shows IC₅₀ values < 0.1 nM against MMP-2, MMP-9, and MMP-13. SC-77964 can be used for the research of cancer and inflammation, such as melanoma.

ASPH-IN-1 (Compound 14c) is an orally active ASPH inhibitor. ASPH-IN-1 down-regulates MMP2 and MMP14 protein expression. ASPH-IN-1 exhibits anti-cancer activity against cholangiocarcinoma.

MMP-9-IN-14 is a MMP-9 inhibitor (IC₅₀ = 34.46 μM). MMP-9-IN-14 induces G1-phase cell cycle arrest and caspase-dependent apoptosis in cancer cells. MMP-9-IN-14 promotes the accumulation of phosphorylated γH2AX. MMP-9-IN-14 inhibits the migration and invasion of cancer cells, and downregulates the expressions of MMP-2, MMP-9 and hTERT in cancer cells. MMP-9-IN-14 inhibits tumor growth and angiogenic spread in animal models. MMP-9-IN-14 can be used for the research of cancers such as lung adenocarcinoma, cervical cancer and colorectal cancer.

CTTHWGFTLC, CYCLIC is a cyclic peptide inhibitor for matrix metalloproteinases MMP-2 and MMP-9. The IC₅₀ value for MMP-9 is ~8 μM.

(E)-N-(4-Methoxyphenyl)cinnamamide is a selective matrix metalloproteinase inhibitor with inhibitory activity against MMP-2 (IC₅₀ = 5.37 nM), MMP-9 (IC₅₀ = 6.21 nM), and low activity against MMP-1 (IC₅₀ = 5301.68 nM). (E)-N-(4-Methoxyphenyl)cinnamamide can be used for the research of tumor.

Alisol B 23-acetate (Standard) is the analytical standard of Alisol B 23-acetate (HY-N0805). This product is intended for research and analytical applications. Alisol B 23-acetate is an orally active prototerpane-type triterpenoid. Alisol B 23-acetate can be isolated from Alisma orientalis. Alisol B 23-acetate induces Apoptosis, promotes ROS generation, downregulates CDK4/6, MMP-2/9, upregulates cleaved PARP, activates FXR and inhibits Syk. Alisol B 23-acetate has anti-inflammatory and hepatoprotective activities. Alisol B 23-acetate protects the kidney from ischemia-reperfusion injury. Alisol B 23-acetate has anticancer activity against ovarian cancer, colon cancer, lung cancer, and gastric cancer. Alisol B 23-acetate can be used in the study of atherosclerosis and allergic asthma.

Lixisenatide (Leu-¹³C₆,¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled Lixisenatide (HY-P0119). Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis.

MMI-166 is an orally active selective matrix metalloproteinase (MMP) inhibitor (MMP-2 (IC₅₀ = 2 nM), MMP-9 (IC₅₀ = 53 nM)). MMI-166 can prevent tumor invasion, metastasis and angiogenic, and promotes apoptosis. MMI-166 dose not only directly inhibits the enzymatic activity of MMP-2 and MMP-9 but also downregulates their protein synthesis and expression levels at the post-transcriptional level. MMI-166 can be used in research on colon cancer, head and neck squamous cell carcinoma, microglioma, lung cancer, and pancreatic cancer.

CIL-102, an apoptosis inducer, is a MMP-2/MMP-9 inhibitor that decreases MMP-2/MMP-9 protein expression and mRNA levels. CIL-102 displays an anti-cancer activity.

Pipoxolan is an orally active smooth muscle relaxant, anti-inflammatory agent and anticancer agent. Pipoxolan modulates PI3K/AKT signaling pathways, and reduces the levels of Ras/MEK/p-ERK, MMP-2 and MMP-9. Pipoxolan inhibits pro-inflammatory transcription factor pathways, activates Nrf2/HO-1, and suppresses the production of pro-inflammatory mediators. Pipoxolan induces ROS generation, endogenous mitochondrial Apoptosis, and G₀/G₁ cell cycle arrest. Pipoxolan reduces cerebral infarction size and inhibits intimal hyperplasia. Pipoxolan can be used in research related to cerebral ischemia, intimal hyperplasia, oral squamous cell carcinoma, leukemia and lung cancer.

SD-7300 (SC-81490) is an orally active inhibitor of MMP-2, MMP-9, and MMP-13 with K_i values ??of 0.03, 0.01, and 0.03 nM, respectively. SD-7300 can reduce the degradation of extracellular matrix by tumor cells, thereby inhibiting the invasion and metastasis of tumor cells. In addition, SD-7300 is also a dose-dependent inhibitor of mouse corneal angiogenesis and an inhibitor of interleukin-1-induced bovine cartilage degradation. SD-7300 can be used in breast cancer research.

Pexmetinib hydrochloride (ARRY-614 hydrochloride) is an orally active dual Tie-2 and p38 MAPK inhibitor. Pexmetinib hydrochloride binds to Tie-2 and p38 MAPK in a "DFG-out" conformation, attenuates the phosphorylation of p38, inhibits STAT3 activation, reduces the promoter-binding activity of NFATc1, and decreases the expression of MMPs. Pexmetinib hydrochloride inhibits leukemia cell proliferation, abrogates TNF-α-mediated myelosuppression of healthy hematopoietic stem cells, stimulates hematopoiesis in primary myelodysplastic syndrome (MDS) samples, inhibits RANKL-induced osteoclast formation and bone resorption, and suppresses migration, invasion and induced osteolysis of breast cancer cells. Pexmetinib hydrochloride can be used in research related to myelodysplastic syndrome, acute myeloid leukemia and breast cancer-induced osteolysis.

ABT-770 (compound 11) is a highly selective and orally active MMP inhibitor, demonstrating over 1000-fold selectivity for MMP-2 (IC₅₀=4 nM) compared to MMP-1 (IC₅₀=4600 nM). ABT-770 can be utilized in studies related to tumor growth, invasion, and metastasis.

3-Aminobenzene-1,2-diol (compound C8) is a matrix metalloproteinase (MMP) inhibitor with IC₅₀ values ​​of 20, 26, 16 and 16.3 μM for MMP-2, MMP-8, MMP-9 and MMP-14, respectively.

(E)-N-(2-Fluorophenyl) cinnamamide (Compound 5m) is a MMP-2 and MMP-9 inhibitor, with selectivity over MMP-1. Its IC₅₀ values against MMP-2, MMP-9 and MMP-1 are 9.09 nM, 8.02 nM and 4117.53 nM, respectively. (E)-N-(2-Fluorophenyl) cinnamamide can be used in the research of metastatic tumors.

LY52 is an MMP-2 and MMP-9 inhibitor. LY52 can significantly block the proteolytic activity of gelatinases, reducing the expression of MMP-2 and MMP-9 in SKOV3 cells, thereby inhibiting cell invasion. LY52 can also suppress the pulmonary metastasis of Lewis lung carcinoma cells in mice. LY52 may be used in cancer research.

CZh226 is a selective PAK4 inhibitor with an IC₅₀ of 0.0111 μM and a K_i of 0.009 μM. CZh226 functionally inhibits PAK4 activity and reduces the phosphorylation level of downstream signaling molecules. CZh226 inhibits the migration and invasion of tumor cells. CZh226 is applicable to lung cancer-related research.

Homorisedronate (NE-58051) is a MMP inhibitor with high bone mineral affinity but low bone antiresorptive activity in vivo. Homorisedronate inhibits the proteolytic activity of MMP-2, MMP-9, and MMP-12 through zinc chelation and phosphonate groups, with IC₅₀ values of 40 μM, 160 μM, and 80 μM for human MMP-2, mouse MMP-9, and rabbit MMP-12, respectively. Homorisedronate inhibits breast cancer and melanoma cell proliferation without inducing MRONJ-like lesions, altering osteoclast activity, or changing serum TRAcP-5b levels. Homorisedronate is suitable for research related to breast cancer and melanoma.

Trilinolein (Standard) is the analytical standard of Trilinolein (HY-128393). This product is intended for research and analytical applications. Trilinolein is an orally active triglyceride that inhibits the PI3K/Akt, Ras/MEK/ERK signaling pathways, and MMP-2. Trilinolein can reduce oxidative stress, induce apoptosis, and inhibit cell migration. Trilinolein can be used in the research fields of cardiovascular disease, cerebrovascular disease (such as cerebral ischemia), and non-small cell lung cancer.